| 摘要 |
<p>The present invention is based on the discovery of an association between the SNP genotype at the rs12979860 locus in the IL28B gene promoter and the probability of achieving a SVR in HC V-infected patients that are given a triple therapy treatment that contains peginterferon alfa-2a, ribavirin, and a HCV NS5B polymerase inhibitor.</p> |
